Mankind Pharma Limited has informed the Exchange about Investor Presentation
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma reported Q4 FY25 revenue of ₹3,079 Cr, up 27.1% YoY, driven by strong export growth of 100% YoY and domestic growth of 18.1%. FY25 revenue grew 19% to ₹12,207 Cr, while adjusted EBITDA margin expanded to 25.9% from 24.6% in FY24. However, Q4 profitability was under pressure with PAT declining 10% YoY to ₹429 Cr and adjusted EBITDA margin contracting to 23.1% from 24.3%. The company raised its IPM market share to 4.8% (from 4.4%) aided by the BSV acquisition, though Q4 secondary sales growth of 6% trailed industry IPM growth of 7.3%. Net debt stood at ₹5,784 Cr with Net Debt/EBITDA at 1.8x, reflecting the BSV acquisition impact.
Mixed quarter with strong top-line growth and improving full-year margins offset by Q4 margin contraction and declining PAT. Rising net debt from BSV acquisition remains a key monitorable. Long-term growth pillars (chronic, OTC, BSV specialty) are intact, but near-term margin pressure and regulatory headwinds in acute segment could weigh on sentiment.